The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease

Nutrients

Volumn 6, Issue 12, 2014, Pages 5583-5599

  Ferolla, Silvia M ^a   Armiliato, Geyza N A ^a   Couto, Cláudia A ^a   Ferrari, Teresa C A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Bacterial translocation; Endotoxemia; Fatty liver; Gut microbiota; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Small intestinal bacterial overgrowth

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; STEROL REGULATORY ELEMENT BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL OVERGROWTH; BODY MASS; ENDOTOXEMIA; GENE EXPRESSION; HUMAN; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIPID STORAGE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; SIGNAL TRANSDUCTION; ANIMAL; BACTERIAL TRANSLOCATION; BACTERIUM; COMPLICATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MICROFLORA; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; RISK FACTOR; SMALL INTESTINE; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS);

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL TRANSLOCATION; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINE, SMALL; MICROBIOTA; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84919385811     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu6125583     Document Type: Article

References (74)

1. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology2012, 55, 2005–2023.
2. Day, C. Pathogenesis of steatohepatitis. Best Pract. Res. Clin. Gastroenterol.2002, 16, 663–678.
3. Sanyal, A.J.; Campbell-Sargent, C.; Mirshahi, F.; Rizzo, W.B.; Contos, M.J.; Sterling, R.K.; Luketic, V.A.; Shiffman, M.L.; Clore, J.N. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology2001, 120, 1183–1192.
4. Chitturi, S.; Abeygunasekera, S.; Farrell, G.C.; Holmes-Walker, J.; Hui, J.M.; Fung, C.; Karim, R.; Lin, R.; Samarasinghe, D.; Liddle, C. et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology2002, 35, 373–379.
5. Iacono, A.; Raso, G.M.; Canani, R.B.; Calignano, A.; Meli, R. Probiotics as an emerging therapeutic strategy to treat NAFLD: Focus on molecular and biochemical mechanisms. J. Nutr. Biochem. 2011, 22, 699–711.
6. Roh, Y.S.; Seki, E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J. Gastroenterol. Hepatol.2013, 28, 38–42.
7. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Microbial ecology: Human gut microbes associated with obesity. Nature2006, 444, 1022–1023.
8. Le Roy, T.; Llopis, M.; Lepage, P.; Bruneau, A.; Rabot, S.; Bevilacqua, C.; Martin, P.; Philippe, C.; Walker, F.; Bado, A. et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013, 62, 1787–1794.
9. Mouzaki, M.; Comelli, E.M.; Arendt, B.M.; Bonengel, J.; Fung, S.K.; Fischer, I.D.; McGilvray, S.; Allard, J.P. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology2013, 58, 120–127.
10. Wigg, A.J.; Roberts-Thomson, I.C.; Dymock, R.B.; McCarthy, P.J.; Grose, R.H.; Cummins, A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut2001, 48, 206–211.
11. Sajjad, A.; Mottershead, M.; Syn, W.K.; Jones, R.; Smith, S.; Nwokolo, C.U. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther.2005, 22, 291–299.
12. Sabaté, J.M.; Jouët, P.; Harnois, F.; Mechler, C.; Msika, S.; Grossin, M.; Coffin, B. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. Obes. Surg.2008, 18, 371–377.
13. Miele, L.; Valenza, V.; la Torre, G.; Montalto, M.; Cammarota, G.; Ricci, R.; Mascianà, R.; Forgione, A.; Gabrieli, M.L.; Perotti, G. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology2009, 49, 1877–1887.
14. Shanab, A.A.; Scully, P.; Crosbie, O.; Buckley, M.; O’Mahony, L.; Shanahan, F.; Gazareen, S.; Murphy, E.; Quigley, E.M. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: Association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig. Dis. Sci.2011, 56, 1524–1534.
15. Volynets, V.; Küper, M.A.; Strahl, S.; Maier, I.B.; Spruss, A.; Wagnerberger, S.; Königsrainer, A.; Bischoff, S.C.; Bergheim, I. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig. Dis. Sci.2012, 57, 1932–1941.
16. Ruiz, A.G.; Casafont, F.; Crespo, J.; Cayón, A.; Mayorga, M.; Estebanez, A.; Fernadez-Escalante, J.C.; Pons-Romero, F. Lipopolysaccharide-binding protein plasma levels and liver TNF-α gene expression in obese patients: Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg.2007, 17, 1374–1380.
17. Neish, A.S. Microbes in gastrointestinal health and disease. Gastroenterology2009, 136, 65–80.
18. Bäckhed, F.; Ding, H.; Wang, T.; Hooper, L.V.; Koh, G.Y.; Nagy, A.; Semenkovich, C.F.; Gordon, J.I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA2004, 101, 15718–15723.
19. Duseja, A.; Chawla, Y.K. Obesity and NAFLD: The Role of Bacteria and Microbiota. Clin. Liver Dis. 2014, 18, 59–71.
20. Zoetendal, E.G.; Vaughan, E.E.; de Vos, W.M. A microbial world within us. Mol. Microbiol.2006, 59, 1639–1650.
21. Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature2006, 444, 1027–1031.
22. Vajro, P.; Paolella, G.; Fasano, A. Microbiota and gut-liver axis: Their influences on obesity and obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr.2013, 56, 461–468.
23. Bellot, P.; Francés, R.; Such, J. Pathological bacterial translocation in cirrhosis: Pathophysiology, diagnosis and clinical implications. Liver Int. 2013, 33, 31–39.
24. Liu, J.; Wu, D.; Ahmed, A.; Li, X.; Ma, Y.; Tang, L.; Mo, D.; Ma, Y.; Xin, Y. Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. Curr. Microbiol.2012, 65, 7–13.
25. Seo, Y.S.; Shah, V.H. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin. Mol. Hepatol. 2012, 18, 337–346.
26. Gupta, A.; Dhiman, R.K.; Kumari, S.; Rana, S.; Agarwal, R.; Duseja, A.; Chawla, Y. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J. Hepatol.2010, 53, 849–855.
27. Fuchs, M. Non-alcoholic fatty liver disease: The bile acid-activated farnesoid X receptor as an emerging treatment target. J. Lipids 2012, doi:10.1155/2012/934396.
28. Kakiyama, G.; Pandak, W.M.; Gillevet, P.M.; Hylemon, P.B.; Heuman, D.M.; Daita, K.; Takei, H.; Muto, A.; Nittono, H.; Ridlon, J.M. et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J. Hepatol.2013, 58, 949–955.
29. Lorenzo-Zúñiga, V.; Bartolí, R.; Planas, R.; Hofmann, A.F.; Viñado, B.; Hagey, L.R.; Hernández, J.M.; Mañé, J.; Alvarez, M.A.; Ausina, V. et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003, 37, 551–557.
30. Xie, G.; Zhong, W.; Li, H.; Li, Q.; Qiu, Y.; Zheng, X.; Chen, H.; Zhao, X.; Zhang, S.; Zhou, Z. et al. Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption. FASEB J. 2013, 27, 3583–3593.
31. Caricilli, A.M.; Saad, M.J. The role of gut microbiota on insulin resistance. Nutrients2013, 5, 829–851.
32. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.; Roe, B.A.; Affourtit, J.P. et al. A core gut microbiome in obese and lean twins. Nature 2009, 457, 480–484.
33. Rychlik, J.L.; May, T. The effect of a methanogen, Methanobrevibacter smithii, on the growth rate, organic acid production, and specific ATP activity of three predominant ruminal cellulolytic bacteria. Curr. Microbiol.2000, 40, 176–180.
34. Zhang, H.; DiBaise, J.K.; Zuccolo, A.; Kudrna, D.; Braidotti, M.; Yu, Y.; Parameswaran, P.; Crowell, M.D.; Wing, R.; Rittmann, B.E. et al. Human gut microbiota in obesity and after gastric bypass. Proc. Natl. Acad. Sci. USA 2009, 106, 2365–2370.
35. Vrieze, A.; van Nood, E.; Holleman, F.; Salojärvi, J.; Kootte, R.S.; Bartelsman, J.F.; Dallinga-Thie, G.M.; Ackermans, M.T.; Serlie, M.J.; Oozeer, R. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143, 913–916.
36. Zhu, L.; Baker, S.S.; Gill, C.; Liu, W.; Alkhouri, R.; Baker, R.D.; Gill, S.R. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology2013, 57, 601–609.
37. Malaguarnera, M.; Vacante, M.; Antic, T.; Giordano, M.; Chisari, G.; Acquaviva, R.; Mastrojeni, S.; Malaguarnera, G.; Mistretta, A.; Li Volti, G. et al. Bifidobacterium longum with fructo-oligosaccharides in patients with nonalcoholic steatohepatitis. Dig. Dis. Sci. 2012, 57, 545–553.
38. Madrid, A.M.; Hurtado, C.; Gatica, S.; Chacon, I.; Toyos, A.; Defilippi, C. Endogenous ethanol production in patients with liver cirrhosis, motor alteration and bacterial overgrowth. Rev. Med. Chile2002, 130, 1329–1334.
39. Szabo, G.; Mandrekar, P.; Dolganiuc, A. Innate immune response and hepatic inflammation. Semin. Liver Dis.2007, 27, 339–350.
40. Aoyama, T.; Paik, Y.H.; Seki, E. Toll-like receptor signaling and liver fibrosis. Gastroenterol. Res. Pract. 2010, doi:10.1155/2010/192543.
41. Meli, R.; Raso, G.M.; Calignano, A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front. Immunol.2014, 5, 177.
42. Seki, E.; Brenner, D.A. Toll-like receptors and adaptor molecules in liver disease: Update. Hepatology 2008, 48, 322–335.
43. Takeuchi, O.; Akira, S. Pattern recognition receptors and inflammation. Cell2010, 140, 805–820.
44. Henao-Mejia, J.; Elinav, E.; Jin, C.; Hao, L.; Mehal, W.Z.; Strowig, T.; Thaiss, C.A.; Kau, A.L.; Eisenbarth, S.C.; Jurczak, M.J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482, 179–185.
45. Cani, P.D.; Amar, J.; Iglesias, M.A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A.M.; Fava, F.; Tuohy, K.M.; Chabo, C. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56, 1761–1772.
46. Bergheim, I.; Weber, S.; Vos, M.; Kramer, S.; Volynets, V.; Kaserouni, S.; McClain, C.J.; Bischoff, S.C. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. J. Hepatol.2008, 48, 983–992.
47. Shimomura, I.; Bashmakov, Y.; Horton, J.D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem.1999, 274, 30028–30032.
48. Matusoka, M.; Tsukamoto, H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor β: Implication for a pathogenic role. Hepatology1990, 11, 599–605.
49. Postic, C.; Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J. Clin. Investig.2008, 118, 829–838.
50. Fukunishi, S.; Sujishi, T.; Takeshita, A.; Ohama, H.; Tsuchimoto, Y.; Asai, A.; Tsuda, Y.; Higuchi, K.; Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J. Clin. Biochem. Nutr.2014, 54, 39–44.
51. Bondar, G.F.; Pisesky, W. Complications of small intestinal shortcircuiting for obesity. Arch. Surg.1967, 94, 707–716.
52. Maxwell, J.G.; Richards, R.C.; Albo, D., Jr. Fatty degeneration of the liver after intestinal bypass for obesity. Am. J. Surg.1968, 116, 648–652.
53. Nazim, M.; Stamp, G.; Hodgson, H.J.F. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology1989, 36, 349–351.
54. Riordan, S.M.; Duncombe, V.M.; Thomas, M.C.; Nagree, A.; Bolin, T.D.; McIver, C.J.; Williams, R. Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis. Gut2002, 50,136–138.
55. Khoshini, R.; Dai, S.C.; Lezcano, S.; Pimentel, M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig. Dis. Sci.2008, 53, 1443–1454.
56. Horváth, V.J.; Izbéki, F.; Lengyel, C.; Kempler, P.; Várkonyi, T. Diabetic gastroparesis: Functional/morphologic background, diagnosis, and treatment options. Curr. Diabetes Rep.2014, 14, 527.
57. Soza, A.; Riquelme, A.; González, R.; Alvarez, M.; Pérez-Ayuso, R.M.; Glasinovic, J.C.; Arrese, M. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig. Dis. Sci.2005, 50, 1136–1140.
58. Fu, X.S.; Jiang, F. Cisapride decreasing orocecal transit time in patients with nonalcoholic steatohepatitis. Hepatobiliary Pancreat. Dis. Int. 2006, 5, 534–537.
59. Thuy, S.; Ladurner, R.; Volynets, V.; Wagner, S.; Strahl, S.; Königsrainer, A.; Maier, K.P.; Bischoff, S.C.; Bergheim, I. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J. Nutr.2008, 138, 1452–1455.
60. Alessi, M.C., Bastelica, D.; Mavri, A.; Morange, P.; Berthet, B.; Grino, M.; Juhan-Vague, I. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler. Thromb. Vasc. Biol.2003, 23, 1262–1268.
61. Bergheim, I.; Guo, L.; Davis, M.A.; Lambert, J.C.; Beier, J.I.; Duveau, I.; Luyendyk, J.P.; Roth, R.A.; Arteel, G.E. Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology2006, 130, 2099–2112.
62. Bergheim, I.; Guo, L.; Davis, M.A.; Duveau, I.; Arteel, G.E. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J. Pharmacol. Exp. Ther.2006, 316, 592–600.
63. Musso, G.; Gambino, R.; de Michieli, F.; Cassader, M.; Rizzetto, M.; Durazzo, M.; Fagà, E.; Silli, B.; Pagano, G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology2003, 37, 909–916.
64. Ouyang, X.; Cirillo, P.; Sautin, Y.; McCall, S.; Bruchette, J.L.; Diehl, A.M.; Johnson, R.J.; Abdelmalek, M.F. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol.2008, 48, 993–999.
65. Volynets, V.; Machann, J.; Küper, M.A.; Maier, I.B.; Spruss, A.; Königsrainer, A.; Bischoff, S.C.; Bergheim, I. A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): A pilot study. Eur. J. Nutr.2013, 52, 527–535.
66. Walker, R.W.; Lê, K.A.; Davis, J.; Alderete, T.L.; Cherry, R.; Lebel, S.; Goran, M.I. High rates of fructose malabsorption are associated with reduced liver fat in obese African Americans. J. Am. Coll. Nutr.2012, 31, 369–374.
67. Wu, W.C.; Zhao, W.; Li, S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J. Gastroenterol.2008, 14, 313–317.
68. Loguercio, C.; de Simone, T.; Federico, A.; Terracciano, F.; Tuccillo, C.; di Chicco, M.; Cartenì, M. Gut-liver axis: A new point of attack to treat chronic liver damage? Am. J. Gastroenterol.2002, 97, 2144–2146.
69. Loguercio, C.; Federico, A.; Tuccillo, C.; Terracciano, F.; D’Auria, M.V.; de Simone, C.; del Vecchio Blanco, C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol.2005, 39, 540–543.
70. Vajro, P.; Mandato, C.; Licenziati, M.R.; Franzese, A.; Vitale, D.F.; Lenta, S.; Caropreso, M.; Vallone, G.; Meli, R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr.2011, 52, 740–743.
71. Aller, R.; de Luis, D.A.; Izaola, O.; Conde, R.; Gonzalez Sagrado, M.; Primo, D.; de la Fuente, B.; Gonzalez, J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci.2011, 15, 1090–1095.
72. Wong, V.W.; Won, G.L.; Chim, A.M.; Chu, W.C.; Yeung, D.K.; Li, K.C.; Chan, H.L. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann. Hepatol.2013, 12, 256–262.
73. Eslamparast, T.; Poustchi, H.; Zamani, F.; Sharafkhah, M.; Malekzadeh, R.; Hekmatdoost, A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am. J. Clin. Nutr.2014, 99, 535–542.
74. Ma, Y.Y.; Li, L.; Yu, CH.; Shen, Z.; Chen, L.H.; Li, Y.M. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J. Gastroenterol.2013, 19, 6911–6918.